TY - BOOK PY - 2012 DA - 2012// TI - Cancer incidence and mortality worldwide: IARC Cancer Base No11. Lyon PB - International Agency for Research on Cancer CY - France ID - ref1 ER - TY - JOUR AU - Armstrong, D. K. AU - Bundy, B. AU - Wenzel, L. AU - Huang, H. Q. AU - Baergen, R. AU - Lele, S. PY - 2006 DA - 2006// TI - Intraperitoneal cisplatin and paclitaxel in ovarian cancer JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa052985 DO - 10.1056/NEJMoa052985 ID - Armstrong2006 ER - TY - JOUR AU - Katsumata, N. AU - Yasuda, M. AU - Isonishi, S. AU - Takahashi, F. AU - Michimae, H. AU - Kimura, E. PY - 2013 DA - 2013// TI - Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70363-2 DO - 10.1016/S1470-2045(13)70363-2 ID - Katsumata2013 ER - TY - JOUR AU - Bookman, M. A. AU - Brady, M. F. AU - McGuire, W. P. AU - Harper, P. G. AU - Alberts, D. S. AU - Friedlander, M. PY - 2009 DA - 2009// TI - Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic Cancer intergroup JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.1684 DO - 10.1200/JCO.2008.19.1684 ID - Bookman2009 ER - TY - JOUR AU - Bookman, M. A. AU - Darcy, K. M. AU - Clarke-Pearson, D. AU - Boothby, R. A. AU - Horowitz, I. R. PY - 2003 DA - 2003// TI - Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.10.104 DO - 10.1200/JCO.2003.10.104 ID - Bookman2003 ER - TY - JOUR AU - Noguera, I. R. AU - Sun, C. C. AU - Broaddus, R. R. AU - Branham, D. AU - Levenback, C. F. AU - Ramirez, P. T. PY - 2012 DA - 2012// TI - Phase II trial of imatinib mesylate in patients with recurrent platinum and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube JO - Gynecol Oncol VL - 125 UR - https://doi.org/10.1016/j.ygyno.2012.02.034 DO - 10.1016/j.ygyno.2012.02.034 ID - Noguera2012 ER - TY - JOUR AU - Sato, S. AU - Itamochi, H. PY - 2012 DA - 2012// TI - Bevacizumab and ovarian cancer JO - Curr Opin Obstet Gynecol VL - 24 UR - https://doi.org/10.1097/GCO.0b013e32834daeed DO - 10.1097/GCO.0b013e32834daeed ID - Sato2012 ER - TY - JOUR AU - Oza, A. M. AU - Cook, A. D. AU - Pfisterer, J. AU - Embleton, A. AU - Ledermann, J. A. AU - Pujade-Lauraine, E. PY - 2015 DA - 2015// TI - Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00086-8 DO - 10.1016/S1470-2045(15)00086-8 ID - Oza2015 ER - TY - JOUR AU - Giornelli, G. H. PY - 2016 DA - 2016// TI - Management of relapsed ovarian cancer: a review JO - Springerplus VL - 5 UR - https://doi.org/10.1186/s40064-016-2660-0 DO - 10.1186/s40064-016-2660-0 ID - Giornelli2016 ER - TY - JOUR AU - du Bois, A. AU - Floquet, A. AU - Kim, J. W. AU - Rau, J. AU - del Campo, J. M. AU - Friedlander, M. PY - 2014 DA - 2014// TI - Incorporation of pazopanib in maintenance therapy of ovarian cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.55.7348 DO - 10.1200/JCO.2014.55.7348 ID - du Bois2014 ER - TY - JOUR AU - Berek, J. AU - Taylor, P. AU - McGuire, W. AU - Smith, L. M. AU - Schultes, B. AU - Nicodemus, C. F. PY - 2009 DA - 2009// TI - Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.17.8400 DO - 10.1200/JCO.2008.17.8400 ID - Berek2009 ER - TY - JOUR AU - Frampton, J. E. PY - 2015 DA - 2015// TI - Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer JO - BioDrugs VL - 29 UR - https://doi.org/10.1007/s40259-015-0125-6 DO - 10.1007/s40259-015-0125-6 ID - Frampton2015 ER - TY - JOUR AU - Mirza, M. R. AU - Monk, B. J. AU - Herrstedt, J. AU - Oza, A. M. AU - Mahner, S. AU - Redondo, A. PY - 2016 DA - 2016// TI - Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611310 DO - 10.1056/NEJMoa1611310 ID - Mirza2016 ER - TY - JOUR AU - Chaffer, C. L. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - A perspective on cancer cell metastasis JO - Science VL - 331 UR - https://doi.org/10.1126/science.1203543 DO - 10.1126/science.1203543 ID - Chaffer2011 ER - TY - JOUR AU - Croker, A. K. AU - Allan, A. L. PY - 2008 DA - 2008// TI - Cancer stem cells: implications for the progression and treatment of metastatic disease JO - J Cell Mol Med VL - 12 UR - https://doi.org/10.1111/j.1582-4934.2007.00211.x DO - 10.1111/j.1582-4934.2007.00211.x ID - Croker2008 ER - TY - JOUR AU - Mimeault, М. AU - Batra, S. K. PY - 2010 DA - 2010// TI - New promising drug targets in cancer- and metastasis-initiating cells JO - Drug Discov Today VL - 15 UR - https://doi.org/10.1016/j.drudis.2010.03.009 DO - 10.1016/j.drudis.2010.03.009 ID - Mimeault2010 ER - TY - JOUR AU - Сhen, K. AU - Huang, Y. H. AU - Chen, J. L. PY - 2013 DA - 2013// TI - Understanding and targeting cancer stem cells: therapeutic implications and challenges JO - Acta Pharmacol Sin VL - 34 UR - https://doi.org/10.1038/aps.2013.27 DO - 10.1038/aps.2013.27 ID - Сhen2013 ER - TY - JOUR AU - Wicha, M. S. AU - Liu, S. AU - Dontu, G. PY - 2006 DA - 2006// TI - Cancer stem cells: an old idea – a paradigm shift JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-3153 DO - 10.1158/0008-5472.CAN-05-3153 ID - Wicha2006 ER - TY - JOUR AU - Foster, R. AU - Buckanovich, R. J. AU - Rueda, B. R. PY - 2013 DA - 2013// TI - Ovarian cancer stem cells: working towards the root of stemness JO - Cancer Lett VL - 338 UR - https://doi.org/10.1016/j.canlet.2012.10.023 DO - 10.1016/j.canlet.2012.10.023 ID - Foster2013 ER - TY - JOUR AU - Ahmed, N. AU - Abubaker, K. AU - Findlay, J. AU - Quinn, M. PY - 2013 DA - 2013// TI - Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance JO - J Cell Biochem VL - 114 UR - https://doi.org/10.1002/jcb.24317 DO - 10.1002/jcb.24317 ID - Ahmed2013 ER - TY - JOUR AU - Steffensen, K. D. AU - Alvero, A. B. AU - Yang, Y. AU - Waldstrom, M. AU - Hui, P. AU - Holmberg, J. C. PY - 2011 DA - 2011// TI - Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer JO - J Oncol VL - 2011 UR - https://doi.org/10.1155/2011/620523 DO - 10.1155/2011/620523 ID - Steffensen2011 ER - TY - JOUR AU - Hosonuma, S. AU - Kobayashi, Y. AU - Kojo, S. AU - Wada, H. AU - Seino, K. AU - Kiguchi, K. PY - 2011 DA - 2011// TI - Clinical significance of side population in ovarian cancer cells JO - Hum Cell VL - 24 UR - https://doi.org/10.1007/s13577-010-0002-z DO - 10.1007/s13577-010-0002-z ID - Hosonuma2011 ER - TY - JOUR AU - Sarkar, F. H. PY - 2010 DA - 2010// TI - Current trends in the chemoprevention of cancer JO - Pharm Res VL - 27 UR - https://doi.org/10.1007/s11095-010-0146-2 DO - 10.1007/s11095-010-0146-2 ID - Sarkar2010 ER - TY - BOOK AU - Kurman, R. J. AU - Сarcanqiu, M. L. AU - Herrington, C. S. AU - Young, R. H. PY - 2014 DA - 2014// TI - WHO Classificaihion of tumours of female reproductive organs PB - IARS CY - Lyon ID - Kurman2014 ER - TY - JOUR AU - Llueca, A. AU - Escrig, J. PY - 2018 DA - 2018// TI - Prognostic value of peritoneal cancer index in primary advanced ovarian cancer JO - Eur J Surg Oncol VL - 44 UR - https://doi.org/10.1016/j.ejso.2017.11.003 DO - 10.1016/j.ejso.2017.11.003 ID - Llueca2018 ER - TY - JOUR AU - Hofmann, M. A. AU - Hauschild, A. AU - Mohr, P. AU - Garbe, C. AU - Weichenthal, M. AU - Trefzer, U. PY - 2011 DA - 2011// TI - Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial JO - Melanoma Res VL - 21 UR - https://doi.org/10.1097/CMR.0b013e3283485ff0 DO - 10.1097/CMR.0b013e3283485ff0 ID - Hofmann2011 ER - TY - JOUR AU - Wright, A. A. AU - Bohlke, K. AU - Armstrong, D. K. AU - Bookman, M. A. AU - Cliby, W. A. AU - Coleman, R. L. PY - 2016 DA - 2016// TI - Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline JO - Gynecol Oncol VL - 143 UR - https://doi.org/10.1016/j.ygyno.2016.05.022 DO - 10.1016/j.ygyno.2016.05.022 ID - Wright2016 ER - TY - JOUR AU - Fagotti, A. AU - Ferrandina, G. AU - Vizzielli, G. AU - Fanfani, F. AU - Gallotta, V. AU - Chiantera, V. PY - 2016 DA - 2016// TI - Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome JO - Eur J Cancer VL - 59 UR - https://doi.org/10.1016/j.ejca.2016.01.017 DO - 10.1016/j.ejca.2016.01.017 ID - Fagotti2016 ER - TY - JOUR AU - Tentes, A. G. AU - Tripsiannis, G. AU - Markakidis, S. AU - Karanikiotis, C. AU - Tzegas, G. AU - Georgiadis, G. PY - 2003 DA - 2003// TI - Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer JO - EJSO VL - 29 UR - https://doi.org/10.1053/ejso.2002.1380 DO - 10.1053/ejso.2002.1380 ID - Tentes2003 ER - TY - JOUR AU - Rustin, G. J. AU - Quinn, M. AU - Thigpen, T. AU - du Bois, A. AU - Pujade-Lauraine, E. AU - Jakobsen, A. PY - 2004 DA - 2004// TI - Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh081 DO - 10.1093/jnci/djh081 ID - Rustin2004 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - STD TI - Kiselev VI. Anti-estrogenic and anti-proliferative agent to treat and prevent female reproductive system diseases Patent (invention) No 2315594, Russian Federation, priority awarded September 01, 2006 (Киселев ВИ. Антиэстрогенное и антипролиферативное средство для лечения и профилактики заболеваний женской репродуктивной системы. Патент на изобретение РФ №2315594, дата приоритета 01 сентября 2006 год). ID - ref32 ER - TY - STD TI - Kiselev VI, Muyzhnek EL. Pharmaceutical composition to prevent metastasis and increase the sensitivity (sensitization) of tumors to chemotherapy Drugs Patent (invention) No 2328282, Russian Federation, priority awarded April 23, 2007 (Киселев ВИ, Муйжнек ЕЛ. Фармацевтическая композиция для профилактики образования метастазов и повышения чувствительности (сенсибилизации) опухолей к химиотерапевтическим препаратам. Патент на изобретение РФ № 2328282, дата приоритета 23 апреля 2007 год). ID - ref33 ER - TY - JOUR AU - Harter, P. AU - du Bois, A. AU - Hahmann, M. AU - Hasenburg, A. AU - Burges, A. AU - Loibl, S. PY - 2006 DA - 2006// TI - Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial JO - Ann Surg Oncol VL - 13 UR - https://doi.org/10.1245/s10434-006-9058-0 DO - 10.1245/s10434-006-9058-0 ID - Harter2006 ER - TY - JOUR AU - Harter, P. AU - Sehouli, J. AU - Reuss, A. AU - Hasenburg, A. AU - Scambia, G. AU - Cibula, D. PY - 2011 DA - 2011// TI - Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO JO - Int J Gynecol Cancer VL - 21 UR - https://doi.org/10.1097/IGC.0b013e31820aaafd DO - 10.1097/IGC.0b013e31820aaafd ID - Harter2011 ER - TY - BOOK AU - Scott, N. W. AU - Fayers, P. M. PY - 2001 DA - 2001// TI - The EORTC QLQ-C30 scoring manual PB - Uropean organisation for research and treatment of Cancer CY - Brussels ID - Scott2001 ER - TY - STD TI - Cancer Therapy Evaluation Program: National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. http://ctep.cancer.gov. Accessed 9 Aug 2006. UR - http://ctep.cancer.gov ID - ref37 ER - TY - JOUR AU - Kaplan, E. L. AU - Meier, P. PY - 1958 DA - 1958// TI - Nonparametric estimation from incomplete observations JO - J Am Stat Assoc VL - 53 UR - https://doi.org/10.1080/01621459.1958.10501452 DO - 10.1080/01621459.1958.10501452 ID - Kaplan1958 ER - TY - JOUR AU - Cox, D. R. PY - 1972 DA - 1972// TI - Regression models and life-tables JO - J R Stat Soc Ser B (Methodological) VL - 34 ID - Cox1972 ER - TY - JOUR AU - Fagotti, A. AU - Costantini, B. AU - Vizzielli, G. AU - Perelli, F. AU - Ercoli, A. AU - Gallotta, V. PY - 2011 DA - 2011// TI - HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome JO - Gynecol Oncol VL - 122 UR - https://doi.org/10.1016/j.ygyno.2011.04.008 DO - 10.1016/j.ygyno.2011.04.008 ID - Fagotti2011 ER - TY - JOUR AU - Fagotti, A. AU - Costantini, B. AU - Petrillo, M. AU - Vizzielli, G. AU - Fanfani, F. AU - Margariti, P. A. PY - 2012 DA - 2012// TI - Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up JO - Gynecol Oncol VL - 127 UR - https://doi.org/10.1016/j.ygyno.2012.09.020 DO - 10.1016/j.ygyno.2012.09.020 ID - Fagotti2012 ER - TY - JOUR AU - Kaye, S. B. AU - Poole, C. J. AU - Dańska-Bidzińska, A. AU - Gianni, L. AU - Del Conte, G. AU - Gorbunova, V. AU - Novikova, E. AU - Strauss, A. AU - Moczko, M. AU - McNally, V. A. AU - Ross, G. AU - Vergote, I. PY - 2012 DA - 2012// TI - A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer JO - Annals of Oncology VL - 24 UR - https://doi.org/10.1093/annonc/mds282 DO - 10.1093/annonc/mds282 ID - Kaye2012 ER - TY - JOUR AU - Burger, R. A. AU - Brady, M. F. AU - Bookman, M. A. AU - Fleming, G. F. AU - Monk, B. J. AU - Huang, H. PY - 2011 DA - 2011// TI - Incorporation of bevacizumab in the primary treatment of ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1104390 DO - 10.1056/NEJMoa1104390 ID - Burger2011 ER - TY - JOUR AU - Ahmed, N. AU - Abubaker, K. AU - Findlay, J. K. PY - 2014 DA - 2014// TI - Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets JO - Mol Asp Med VL - 39 UR - https://doi.org/10.1016/j.mam.2013.06.002 DO - 10.1016/j.mam.2013.06.002 ID - Ahmed2014 ER - TY - JOUR AU - Conic, I. AU - Dimov, I. AU - Tasic-Dimov, D. AU - Djordjevic, B. AU - Stefanovic, V. PY - 2012 DA - 2012// TI - Ovarian epithelial cancer stem cells JO - Sci World J VL - 11 UR - https://doi.org/10.1100/tsw.2011.112 DO - 10.1100/tsw.2011.112 ID - Conic2012 ER - TY - JOUR AU - Curley, M. D. AU - Garrett, L. A. AU - Schorge, J. O. AU - Foster, R. AU - Rueda, B. R. PY - 2011 DA - 2011// TI - Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer JO - Front Biosci (Landmark Ed) VL - 16 UR - https://doi.org/10.2741/3693 DO - 10.2741/3693 ID - Curley2011 ER - TY - JOUR AU - Djordjevic, B. AU - Stojanovic, S. AU - Conic, I. AU - Jankovic-Velickovic, L. AU - Vukomanovic, P. AU - Zivadinovic, R. PY - 2012 DA - 2012// TI - Current approach to epithelial ovarian cancer based on the concept of cancer stem cells JO - J BUON VL - 17 ID - Djordjevic2012 ER - TY - JOUR AU - Abubaker, K. AU - Latifi, A. AU - Luwor, R. AU - Nazaretian, S. AU - Zhu, H. AU - Quinn, M. A. PY - 2013 DA - 2013// TI - Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden JO - Mol Cancer VL - 12 UR - https://doi.org/10.1186/1476-4598-12-24 DO - 10.1186/1476-4598-12-24 ID - Abubaker2013 ER - TY - JOUR AU - Latifi, A. AU - Luwor, R. B. AU - Bilandzic, M. AU - Nazaretian, S. AU - Stenvers, K. AU - Pyman, J. PY - 2012 DA - 2012// TI - Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0046858 DO - 10.1371/journal.pone.0046858 ID - Latifi2012 ER - TY - JOUR AU - Kwon, M. J. AU - Shin, Y. K. PY - 2013 DA - 2013// TI - Regulation of ovarian cancer stem cells or tumor-initiating cells JO - Int J Mol Sci VL - 14 UR - https://doi.org/10.3390/ijms14046624 DO - 10.3390/ijms14046624 ID - Kwon2013 ER - TY - JOUR AU - Wenga, J. R. AU - Tsaic, C. H. AU - Kulp, S. K. AU - Che, C. S. PY - 2008 DA - 2008// TI - Indole-3-carbinol as a chemopreventive and anti-cancer agent JO - Cancer Lett VL - 262 UR - https://doi.org/10.1016/j.canlet.2008.01.033 DO - 10.1016/j.canlet.2008.01.033 ID - Wenga2008 ER - TY - JOUR AU - Banerjee, S. AU - Kong, D. AU - Wang, Z. AU - Bao, B. AU - Hillman, G. G. AU - Sarkar, F. H. PY - 2011 DA - 2011// TI - Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM): from bench to clinic JO - Mutat Res VL - 728 UR - https://doi.org/10.1016/j.mrrev.2011.06.001 DO - 10.1016/j.mrrev.2011.06.001 ID - Banerjee2011 ER - TY - JOUR AU - Maruthanila, V. L. AU - Poornima, J. AU - Mirunalini, S. PY - 2014 DA - 2014// TI - Attenuation of carcinogenesis and the mechanism underlying by the influence of indole-3-carbinol and its metabolite 3,3′-diindolylmethane: a therapeutic marvel JO - Adv Pharmacol Sci VL - 2014 ID - Maruthanila2014 ER - TY - JOUR AU - Khan, N. AU - Mukhtar, H. PY - 2008 DA - 2008// TI - Multitargeted therapy of cancer by green tea polyphenols JO - Cancer Lett VL - 269 UR - https://doi.org/10.1016/j.canlet.2008.04.014 DO - 10.1016/j.canlet.2008.04.014 ID - Khan2008 ER - TY - JOUR AU - Kandala, P. K. AU - Srivastava, S. K. PY - 2012 DA - 2012// TI - DIMming ovarian cancer growth JO - Curr Drug Targets VL - 13 UR - https://doi.org/10.2174/138945012804545650 DO - 10.2174/138945012804545650 ID - Kandala2012 ER - TY - JOUR AU - Trudel, D. AU - Labbé, D. P. AU - Bairati, I. AU - Fradet, V. AU - Bazinet, L. AU - Tetu, B. PY - 2012 DA - 2012// TI - Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies JO - Gynecol Oncol VL - 126 UR - https://doi.org/10.1016/j.ygyno.2012.04.048 DO - 10.1016/j.ygyno.2012.04.048 ID - Trudel2012 ER - TY - JOUR AU - Zou, M. AU - Zhang, X. AU - Xu, C. PY - 2016 DA - 2016// TI - IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells JO - Cell Oncol (Dordr) VL - 39 UR - https://doi.org/10.1007/s13402-015-0251-7 DO - 10.1007/s13402-015-0251-7 ID - Zou2016 ER - TY - JOUR AU - Wu, T. Y. AU - Khor, T. O. AU - Su, Z. Y. AU - Saw, C. L. AU - Shu, L. AU - Cheung, K. L. PY - 2013 DA - 2013// TI - Epigenetic modifications of Nrf2 by 3,3′-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors JO - The AAPS J VL - 15 UR - https://doi.org/10.1208/s12248-013-9493-3 DO - 10.1208/s12248-013-9493-3 ID - Wu2013 ER - TY - JOUR AU - Haefele, A. AU - Word, B. AU - Yongmei, X. AU - Hammons, G. J. AU - Lyn-Cook, B. D. PY - 2007 DA - 2007// TI - Indole-3-carbinol (I3C) modulates expression of DNA methyltransferases 1, 3a, and 3b in pancreatic cancer cells: effects of gender and a novel (C→T) polymorphism in the promoter region of DNMT 3b JO - Int J Cancer Prev VL - 2 ID - Haefele2007 ER - TY - JOUR AU - Fang, M. Z. AU - Wang, Y. AU - Ai, N. AU - Hou, Z. AU - Sun, Y. AU - Lu, H. PY - 2003 DA - 2003// TI - Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines JO - Cancer Res VL - 63 ID - Fang2003 ER - TY - JOUR AU - Lyn-Cook, B. D. AU - Mohammed, S. I. AU - Davis, C. AU - Word, B. AU - Haefele, A. AU - Wang, H. PY - 2010 DA - 2010// TI - Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol JO - Anticancer Res VL - 30 ID - Lyn-Cook2010 ER - TY - JOUR AU - Li, Y. AU - Li, X. AU - Guo, B. PY - 2010 DA - 2010// TI - Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-1924 DO - 10.1158/0008-5472.CAN-09-1924 ID - Li2010 ER - TY - JOUR AU - Pandey, M. AU - Shukla, S. AU - Gupta, S. PY - 2010 DA - 2010// TI - Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells JO - Int J Cancer VL - 126 ID - Pandey2010 ER - TY - JOUR AU - Beaver, L. M. AU - Yu, T. W. AU - Sokolowski, E. I. AU - Williams, D. E. AU - Dashwood, R. H. AU - Ho, E. PY - 2012 DA - 2012// TI - 3,3′-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells JO - Toxicol Appl Pharmacol VL - 263 UR - https://doi.org/10.1016/j.taap.2012.07.007 DO - 10.1016/j.taap.2012.07.007 ID - Beaver2012 ER - TY - JOUR AU - Li, Y. AU - Tollefsbol, T. O. PY - 2010 DA - 2010// TI - Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components JO - Curr Med Chem VL - 17 UR - https://doi.org/10.2174/092986710791299966 DO - 10.2174/092986710791299966 ID - Li2010 ER - TY - JOUR AU - Li, Y. AU - Kong, D. AU - Wang, Z. AU - Sarkar, F. H. PY - 2010 DA - 2010// TI - Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research JO - Pharm Res VL - 27 UR - https://doi.org/10.1007/s11095-010-0105-y DO - 10.1007/s11095-010-0105-y ID - Li2010 ER - TY - JOUR AU - Tin, A. S. AU - Park, A. H. AU - Sundar, S. N. AU - Firestone, G. L. PY - 2014 DA - 2014// TI - Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells JO - BMC Biol VL - 12 UR - https://doi.org/10.1186/s12915-014-0072-6 DO - 10.1186/s12915-014-0072-6 ID - Tin2014 ER - TY - JOUR AU - Semov, A. AU - Iourtchenco, L. AU - Liu, L. F. AU - Li, S. AU - Yan, X. AU - Xiaoxue, S. PY - 2012 DA - 2012// TI - Diindolylmethane (DIM) selectively inhibits cancer stem cells JO - Biochem Biophys Res Commun VL - 424 UR - https://doi.org/10.1016/j.bbrc.2012.06.062 DO - 10.1016/j.bbrc.2012.06.062 ID - Semov2012 ER - TY - JOUR AU - Kong, D. AU - Sethi, S. AU - Li, Y. AU - Chen, W. AU - Sakr, W. A. AU - Heath, E. PY - 2015 DA - 2015// TI - Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes JO - Prostate VL - 75 UR - https://doi.org/10.1002/pros.22901 DO - 10.1002/pros.22901 ID - Kong2015 ER - TY - JOUR AU - Chen, D. AU - Banerjee, S. AU - Cui, Q. C. AU - Kong, D. AU - Sarkar, F. H. AU - Dou, Q. P. PY - 2012 DA - 2012// TI - Activation of AMP-activated protein kinase by 3,3′-diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0047186 DO - 10.1371/journal.pone.0047186 ID - Chen2012 ER - TY - JOUR AU - Lin, С. Н. AU - Shen, Y. A. AU - Hung, P. H. AU - Yu, Y. B. AU - Chen, Y. J. PY - 2012 DA - 2012// TI - Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines JO - BMC Complement Altern Med. VL - 12 UR - https://doi.org/10.1186/1472-6882-12-201 DO - 10.1186/1472-6882-12-201 ID - Lin2012 ER - TY - JOUR AU - Li, Y. AU - Wicha, M. S. AU - Schwartz, S. J. AU - Suna, D. PY - 2011 DA - 2011// TI - Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds JO - J Nutr Biochem VL - 22 UR - https://doi.org/10.1016/j.jnutbio.2010.11.001 DO - 10.1016/j.jnutbio.2010.11.001 ID - Li2011 ER - TY - JOUR AU - Nishimura, N. AU - Hartomo, T. B. AU - Pham, T. V. AU - Lee, M. J. AU - Yamamoto, T. AU - Morikawa, S. PY - 2012 DA - 2012// TI - Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells JO - Environ Health Prev Med VL - 17 UR - https://doi.org/10.1007/s12199-011-0239-5 DO - 10.1007/s12199-011-0239-5 ID - Nishimura2012 ER - TY - JOUR AU - Tang, S. N. AU - Fu, J. AU - Nall, D. AU - Rodova, M. AU - Shankar, S. AU - Srivastava, R. K. PY - 2012 DA - 2012// TI - Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.26323 DO - 10.1002/ijc.26323 ID - Tang2012 ER - TY - JOUR AU - Ho, J. N. AU - Jun, W. AU - Choue, R. AU - Lee, J. PY - 2013 DA - 2013// TI - I3C and ICZ inhibit migration by suppressing the EMT process and FAK expression in breast cancer cells JO - Mol Med Rep VL - 7 UR - https://doi.org/10.3892/mmr.2012.1198 DO - 10.3892/mmr.2012.1198 ID - Ho2013 ER - TY - JOUR AU - Sarkar, F. H. AU - Li, Y. AU - Wang, Z. AU - Kong, D. PY - 2010 DA - 2010// TI - The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer JO - Cancer Metastasis Rev VL - 29 UR - https://doi.org/10.1007/s10555-010-9233-4 DO - 10.1007/s10555-010-9233-4 ID - Sarkar2010 ER - TY - JOUR AU - Wang, X. AU - Jiang, P. AU - Wang, P. AU - Yang, C. S. AU - Wang, X. AU - Feng, Q. PY - 2015 DA - 2015// TI - EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0125402 DO - 10.1371/journal.pone.0125402 ID - Wang2015 ER - TY - JOUR AU - Tan, D. S. AU - Agarwal, R. AU - Kaye, S. B. PY - 2006 DA - 2006// TI - Mechanisms of transcoelomic metastasis in ovarian cancer JO - Lancet Oncol. VL - 7 UR - https://doi.org/10.1016/S1470-2045(06)70939-1 DO - 10.1016/S1470-2045(06)70939-1 ID - Tan2006 ER - TY - JOUR AU - Carmignani, C. P. AU - Sugarbaker, T. A. AU - Bromley, C. M. AU - Sugarbaker, P. H. PY - 2003 DA - 2003// TI - Intraperitoneal cancer dissemination: mechanisms of the patterns of spread JO - Cancer Metastasis Rev VL - 22 UR - https://doi.org/10.1023/A:1023791229361 DO - 10.1023/A:1023791229361 ID - Carmignani2003 ER - TY - JOUR AU - Friedlander, M. AU - Trimble, E. AU - Tinker, A. AU - Alberts, D. AU - Avall-Lundqvist, E. AU - Brady, M. PY - 2011 DA - 2011// TI - Clinical trials in recurrent ovarian cancer JO - Int J Gynecol Cancer VL - 21 UR - https://doi.org/10.1097/IGC.0b013e31821bb8aa DO - 10.1097/IGC.0b013e31821bb8aa ID - Friedlander2011 ER - TY - JOUR AU - Coates, A. AU - Porzsolt, F. AU - Osoba, D. PY - 1997 DA - 1997// TI - Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy JO - Eur J Cancer VL - 33 UR - https://doi.org/10.1016/S0959-8049(97)00049-X DO - 10.1016/S0959-8049(97)00049-X ID - Coates1997 ER - TY - JOUR AU - Eton, D. AU - Fairclough, D. AU - Cella, D. AU - Yount, S. E. AU - Bonomi, P. AU - Johnson, D. H. PY - 2003 DA - 2003// TI - Early change in patient reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592 JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.07.128 DO - 10.1200/JCO.2003.07.128 ID - Eton2003 ER - TY - JOUR AU - Dancey, J. AU - Zee, B. AU - Osoba, D. AU - Whitehead, M. AU - Lu, F. AU - Kaizer, L. PY - 1997 DA - 1997// TI - Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group JO - Qual Life Res VL - 6 UR - https://doi.org/10.1023/A:1026442201191 DO - 10.1023/A:1026442201191 ID - Dancey1997 ER - TY - STD TI - Kiselev VI, Smetnik VP, Suturina LV, Selivanov SP, Rudakova EB, Rakhmatullina IR, et al. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology (Russia). 2013; N7:56–62 (Киселев ВИ, Сметник ВП, Сутурина ЛВ, Селиванов СП, Рудакова ЕБ, Рахматуллина ИР и др. Индолкарбинол (Индинол Форто) – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; N7:56–62). ID - ref84 ER - TY - STD TI - Ashrafyan LA, Kiselev VI, Paltsev MA, Kuznetsov IN, Muizhnek EL, Antonova IB, et al. Method to treat ovarian cancer, variants of its metastasis and recurrence. Patent (invention) No 2582939, Russian Federation, priority awarded June 06, 2015 (Ашрафян ЛА, Киселев ВИ, Пальцев МА, Кузнецов ИН, Муйжнек ЕЛ, Антонова ИБ и др. Способ лечения рака яичников, вариантов его метастазирования и рецидивирования. Патент на изобретение РФ №2582939, дата приоритета 06 июня 2015 года). ID - ref85 ER -